What Researchers Did
Researchers investigated the combined use of hyperbaric oxygen and radioionated meta-Iodobenzylguanidine (MIBG) to improve survival in children with recurrent neuroblastoma stage IV.
What They Found
At 28 months, the cumulative probability of survival was 32% for patients treated with [131I]MIBG and hyperbaric oxygen. This compared to 12% for patients receiving [131I]MIBG treatment alone, suggesting a potential improvement.
What This Means for Canadian Patients
For Canadian children with recurrent neuroblastoma stage IV, this study offers preliminary hope for improved survival outcomes. The combination of hyperbaric oxygen and MIBG therapy could potentially extend life in a patient group with otherwise very poor prognosis.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
The researchers noted that these were preliminary results requiring further studies to confirm substantial therapeutic gain.